Scarica l'app Stockscreener
6.02
0.66%
-0.04
Dopo l'orario di chiusura:
6.02
Precedente Chiudi:
$6.06
Aprire:
$6.3
Volume 24 ore:
25,534
Relative Volume:
0.25
Capitalizzazione di mercato:
$103.42M
Reddito:
$35.58M
Utile/perdita netta:
$-17.89M
Rapporto P/E:
-8.8231
EPS:
-0.6823
Flusso di cassa netto:
$-17.74M
1 W Prestazione:
+7.69%
1M Prestazione:
-13.75%
6M Prestazione:
-10.28%
1 anno Prestazione:
-1.59%
Intervallo 1D:
$6.01
$6.30
Intervallo di 1 settimana:
$5.48
$6.30
Portata 52W:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Nome
Verrica Pharmaceuticals Inc
Settore
Industria
Telefono
484-453-3300
Indirizzo
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.02 | 104.10M | 35.58M | -17.89M | -17.74M | -0.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2023-03-22 | Iniziato | Jefferies | Buy |
| 2023-02-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-24 | Iniziato | Northland Capital | Outperform |
| 2020-03-24 | Iniziato | Needham | Buy |
| 2019-02-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
VRCA Assumed by HC Wainwright & Co. -- Buy Rating Announced - GuruFocus
Number of shareholders of Verrica Pharmaceuticals Inc. – LSX:A41A98 - TradingView
Verrica Expands YCANTH Sales as Wart Trials Advance - MyChesCo
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: Verrica Pharmaceuticals Q1 2026 shows revenue growth - Investing.com Nigeria
Verrica Pharmaceuticals Q1 earnings call highlights - MSN
VRCA Stock Price, Quote & Chart | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals Inc. (VRCA) reports Q1 loss, tops revenue estimates - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q1 2026 Earnings Call Transcript - Insider Monkey
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call - Sahm
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Sahm
Verrica Pharmaceuticals (VRCA) Returns To Larger Q1 Loss Challenging Bullish Profitability Narratives - Sahm
Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially - MSN
Verrica (VRCA) Q1 2026 Earnings Transcript - AOL.com
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 2026 Growth for YCANTH - GuruFocus
Verrica Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Q1 Earnings Call Highlights - inkl
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 Revenue Growth - GuruFocus
VRCA: Record Q1 growth for YCANTH, pipeline progress, and global expansion drive positive outlook - TradingView
Verrica Pharmaceuticals 1Q Rev $5.02M >VRCA - Moomoo
Verrica Pharmaceuticals (VRCA) Q1 2026: EPS Not Disclosed (Est - GuruFocus
VRCA: Record YCANTH growth, robust pipeline progress, and strong cash position highlight Q1 2026 - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
[10-Q] Verrica Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum - ChartMill
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Verrica (NASDAQ: VRCA) Q1 revenue hits $5.0M as YCANTH demand grows - Stock Titan
Earnings Call Summary | Verrica Pharmaceuticals(VRCA.US) Q1 2026 Earnings Conference - 富途牛牛
MSN Money - MSN
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Positive Phase II data on Verrica and Lytix’ ruxotemitide in BCC - The Pharma Letter
Lytix Biopharma ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma - Finansavisen
In 9 patients, Verrica's skin cancer drug shrank untreated tumors 67% - Stock Titan
Verrica Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 - The Manila Times
Verrica schedules May 12 webcast for Q1 results and update - Stock Titan
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ... - Caledonian Record
Verrica Pharmaceuticals to Report First Quarter 2026 - GlobeNewswire
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting - Yahoo Finance
Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):